Open access
Open access
Powered by Google Translator Translator

Chest Medicine

[Press release – not published yet] REGENERON reports positive interim data with antibody cocktail used as passive vaccine to prevent COVID-19

27 Jan, 2021 | 01:21h | UTC

REGENERON REPORTS POSITIVE INTERIM DATA WITH REGEN-COV™ ANTIBODY COCKTAIL USED AS PASSIVE VACCINE TO PREVENT COVID-19

Commentaries: Regeneron’s antibody cocktail effective in preventing COVID-19 infection: study – Reuters AND Regeneron says monoclonal antibodies prevent Covid-19 in study – STAT AND Expert reaction to press release from Regeneron giving interim data from its REGEN-COV™ antibody cocktail trial for the prevention of COVID-19 in people at high risk of infection – Science Media Centre

 

Systematic review: Cardiopulmonary resuscitation in the prone position in the operating room or in the intensive care unit

27 Jan, 2021 | 01:14h | UTC

Cardiopulmonary Resuscitation in the Prone Position in the Operating Room or in the Intensive Care Unit: A Systematic Review – Anesthesia & Analgesia

 

Commentary on Twitter (thread – click for more)

https://twitter.com/IARS_Journals/status/1350827861016535043

 

Podcast: Smoking Cessation Unfiltered

26 Jan, 2021 | 00:41h | UTC

#252 Smoking Cessation Unfiltered: Breaking the Chain with Medications and Behavioral Interventions – The Curbsiders Internal Medicine Podcast

 

Report: UK variant of Coronavirus possibly more deadly

26 Jan, 2021 | 00:58h | UTC

NERVTAG paper on COVID-19 variant of concern B.1.1.7

Commentaries: Coronavirus: UK variant ‘may be more deadly’ – BBC AND CDC reviewing new data that suggests coronavirus variant identified in UK could be more deadly – CNN

 

Why scientists are more worried about the Covid-19 variant discovered in South Africa

26 Jan, 2021 | 00:56h | UTC

Why scientists are more worried about the Covid-19 variant discovered in South Africa – Vox

Original study (preprint and commentaries): South African COVID-19 variant escapes neutralization by antibodies in COVID-19 convalescent plasma

See also: Fast-spreading COVID variant can elude immune responses – Nature

 

Commentary on Twitter

 

[Press release – not published yet] Azithromycin and doxycycline are not generally effective against COVID-19 in patients treated at home, shows PRINCIPLE trial

26 Jan, 2021 | 01:03h | UTC

Azithromycin and doxcycline are not generally effective against COVID-19 in patients treated at home, shows PRINCIPLE trial – University of Oxford

See also: PRINCIPLE trial finds no benefit from antibiotics, azithromycin and doxycycline for COVID-19 patients – National Institute for Health Research

 

Moderna COVID-19 vaccine may be less effective against variant found in South Africa

26 Jan, 2021 | 00:54h | UTC

Moderna Finds COVID-19 Vaccine Less Effective Against Variant Found In South Africa – NPR

Moderna Press release: Moderna COVID-19 Vaccine Retains Neutralizing Activity Against Emerging Variants First Identified in the U.K. and the Republic of South Africa

Preprint: mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants – bioRxiv

See also: Expert reaction to preprint from Moderna about neutralising activity of their vaccine against new variants and announcement of plans to trial a variant booster jab targeting the South African (B.1.351) variant – Science Media Centre AND Moderna Launches Trial For Covid-19 Vaccine Booster To Tackle South African Strain – Forbes

 

Commentary on Twitter

 

Meta-analysis: Effect of micronutrient supplements on influenza and other respiratory tract infections among adults

25 Jan, 2021 | 01:17h | UTC

Effect of micronutrient supplements on influenza and other respiratory tract infections among adults: a systematic review and meta-analysis – BMJ Global Health

 

Commentary on Twitter (thread – click for more)

 

 

[Press Release – Not Published Yet] Colchicine reduces the risk of COVID-19-related complications: Positive results from COLCORONA trial show that colchicine is the only effective oral medication for treating non-hospitalized patients

25 Jan, 2021 | 01:43h | UTC

Colchicine reduces the risk of COVID-19-related complications: Positive results from COLCORONA trial show that colchicine is the only effective oral medication for treating non-hospitalized patients – Montreal Heart Insititute

Study Protocol: Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) (COVID-19) – ClinicalTrials.gov

“Patients will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days.”

Commentaries: ‘Major breakthrough’ | Large study shows effectiveness of colchicine to treat COVID-19 – The Canadian AND A gout drug shows promise for Covid-19, but skeptics worry about trusting science by press release – STAT

 

Commentary on Twitter

 

[Press Release – Not Published Yet] Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients

25 Jan, 2021 | 01:42h | UTC

Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients – National Institutes of Health

 

Randomized trial: Bamlanivimab associated with Etesevimab reduce the viral load in patients with mild to moderate COVID-19

25 Jan, 2021 | 01:36h | UTC

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial – JAMA

Editorial: Neutralizing Monoclonal Antibody for Mild to Moderate COVID-19

 

Randomized trial: Anakinra (IL-1 receptor antagonist) does not improve outcomes in patients with mild-to-moderate COVID-19

25 Jan, 2021 | 01:37h | UTC

Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial – The Lancet Respiratory Medicine

Commentary: The right place for IL-1 inhibition in COVID-19 – The Lancet Respiratory Medicine

 

Commentary on Twitter

 

Systematic review: At least one third of SARS-CoV-2 infections are asymptomatic

25 Jan, 2021 | 01:33h | UTC

The Proportion of SARS-CoV-2 Infections That Are Asymptomatic: A Systematic Review – Annals of Internal Medicine

Commentary from the authors: The day we let Covid-19 spin out of control – STAT

 

CDC Report: Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine

25 Jan, 2021 | 01:29h | UTC

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine — United States, December 21, 2020–January 10, 2021 – CDC Morbidity and Mortality Weekly Report

Commentary: CDC reports rare allergic reactions to Moderna’s Covid-19 vaccine – STAT

 

Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline

25 Jan, 2021 | 01:35h | UTC

Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline – The BMJ

Original Guideline: COVID-19 rapid guideline: managing the long-term effects of COVID-19 – National Institute for Health and Care Excellence

 

Randomized trial: No benefit from corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients

25 Jan, 2021 | 01:28h | UTC

Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients: A randomized controlled trial – American Journal of Otolaryngology

 

Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

25 Jan, 2021 | 01:11h | UTC

Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up – Annals of Oncology

 

Systematic Review: Topical antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving mechanical ventilation

25 Jan, 2021 | 01:05h | UTC

Topical antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving mechanical ventilation – Cochrane Library

Summary: Topical antibiotics to help reduce death and respiratory infections in people in intensive care receiving mechanical ventilation – Cochrane Library

 

[News release – Not published yet] Lilly’s neutralizing antibody prevented COVID-19 at nursing homes, reducing risk by up to 80 percent for residents

22 Jan, 2021 | 08:40h | UTC

Lilly’s neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents

Commentaries: Eli Lilly says its monoclonal antibody prevented Covid-19 infections in clinical trial – STAT AND Expert reaction to press release from Lilly about their neutralising antibody bamlanivimab and results from the BLAZE-2 trial looking at prevention of COVID-19 in nursing homes in the US – Science Media Centre

 

Airborne transmission of SARS-CoV-2: What we know

22 Jan, 2021 | 08:38h | UTC

Airborne Transmission of SARS-CoV-2: What We Know – Clinical Infectious Diseases

 

Commentary on Twitter

 

Clinical update: Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine

22 Jan, 2021 | 08:35h | UTC

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine – JAMA

Author interview: COVID-19 Vaccine Safety–Anaphylaxis and Allergic Reactions

 

Large cohort study identifies the most common hospital complications associated with COVID-19

22 Jan, 2021 | 08:36h | UTC

Diagnosis-wide analysis of COVID-19 complications: an exposure-crossover study – Canadian Medical Association Journal

Commentaries: Analysis of patient data reveals most common complications of COVID-19 – Medical News Today AND Study confirms most common complications associated with COVID-19 – New Medical

 

Commentary on Twitter

 

Patients, clinicians seek answers to the mystery of ‘Long COVID’

22 Jan, 2021 | 08:32h | UTC

Patients, clinicians seek answers to the mystery of ‘Long COVID’ – CIDRAP

 

Twenty articles that critical care clinicians should read about COVID-19

22 Jan, 2021 | 08:28h | UTC

Twenty articles that critical care clinicians should read about COVID-19 – Intensive Care Medicine

 

Commentary on Twitter

 

Randomized trial: Benralizumab effects on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma

22 Jan, 2021 | 07:59h | UTC

Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial – The Lancet Respiratory Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.